Moxifloxacin hydrochloride (MOXI) and Dexamethasone sodium phosphate (DEXA) are used in combined dosage form for the treatment of steroid-responsive inflammatory ocular conditions. Literature describes, no method has been reported for the simultaneous estimation of MOXI and DEXA in combined dosage form by UV spectrophotometry. For the simultaneous estimation of MOXI and DEXA by two UV spectrophotometry methods have been developed. The, (1) First order derivative method, and (2) Second order derivative method has been developed. For the linearity for MOXI and DEXA are lies between 30-60 µg/mL and 6-12 µg/mL respectively with co-relation co-efficient > 0.990. The solvent is used is Distilled Water. For the first order derivative method the wavelength selected are 241.30 nm for MOXI and 261.90 nm for DEXA, for the second order derivative method the wavelength selected are 266 nm for MOXI and 241 nm for DEXA. All the developed methods are validated according to ICH guidelines. The proposed methods for estimation of MOXI and DEXA were found to be simple, precise, accurate, economical and statistically validated and are applicable for the simultaneous determination of MOXI and DEXA in ophthalmic dosage form.
Loading....